DEADLINE TOMORROW: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success and commercial potential [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study on October 6, 2025, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].